SYNGENENSEQ1 FY26July 24, 2025

Syngene International Limited

4,413words
3turns
0analyst exchanges
0executives
Key numbers — 40 extracted
Rs 875
Q1 FY26 performance Operating Highlights Q1 FY26 Financial Highlights Revenue from Operations Rs 875 Cr ( 11% Y-o-Y) USD 102 Mn* Operating EBITDA margin 23.6% (21.5% in Q1 FY25) Reported PAT before
11%
rformance Operating Highlights Q1 FY26 Financial Highlights Revenue from Operations Rs 875 Cr ( 11% Y-o-Y) USD 102 Mn* Operating EBITDA margin 23.6% (21.5% in Q1 FY25) Reported PAT before exceptio
23.6%
l Highlights Revenue from Operations Rs 875 Cr ( 11% Y-o-Y) USD 102 Mn* Operating EBITDA margin 23.6% (21.5% in Q1 FY25) Reported PAT before exceptional items : Rs 87 Cr (59% YoY) • • • • • Syng
21.5%
ights Revenue from Operations Rs 875 Cr ( 11% Y-o-Y) USD 102 Mn* Operating EBITDA margin 23.6% (21.5% in Q1 FY25) Reported PAT before exceptional items : Rs 87 Cr (59% YoY) • • • • • Syngene suc
Rs 87
102 Mn* Operating EBITDA margin 23.6% (21.5% in Q1 FY25) Reported PAT before exceptional items : Rs 87 Cr (59% YoY) • • • • • Syngene successfully completed a USFDA Good Clinical Practices (GCP) i
59%
perating EBITDA margin 23.6% (21.5% in Q1 FY25) Reported PAT before exceptional items : Rs 87 Cr (59% YoY) • • • • • Syngene successfully completed a USFDA Good Clinical Practices (GCP) inspecti
INR 86
e top 20 lifescience companies globally *INR converted into USD at the exchange rate of 1 USD = ~ INR 86 Putting Science to Work 5 2 Syngene – Putting Science to Work Partner in innovation: #Putting Sc
Rs. 5 Billion
olecules • Extension of collaboration with BMS; • Merger of Clinigene • Crossed annual turnover of Rs. 5 Billion Foundation • Operations started • Expansion of R&D Lab • Granted 100% EOU status by the Governme
100%
annual turnover of Rs. 5 Billion Foundation • Operations started • Expansion of R&D Lab • Granted 100% EOU status by the Government of India 1993 – 2000 2010 – 2014 2001 – 2009 Expansion • Exp
Rs. 3,642
Hyderabad and Mangalore in India and Baltimore in USA qualified to meet international standards Rs. 3,642 Cr (US$430* Mn) FY25 Revenue from operations Rs. 475 Cr** FY25 PAT 8,235 headcount including 5,6
Rs. 475
qualified to meet international standards Rs. 3,642 Cr (US$430* Mn) FY25 Revenue from operations Rs. 475 Cr** FY25 PAT 8,235 headcount including 5,641 talented scientists 92% energy from renewable sour
92%
enue from operations Rs. 475 Cr** FY25 PAT 8,235 headcount including 5,641 talented scientists 92% energy from renewable sources * All figures are as on March 31, 2025 / FY2025 **before exception
Speaking time
Integrated services
1
IR Contact
1
Media Contact
1
Opening remarks
Integrated services
• • • Manufacturing Research Services Development and for small/large molecules • • • • Product Based Biosimilars Formulations and Compounds Alternative Therapeutic Drugs Putting Science to Work 28 Shareholding and Share Information Syngene’s shareholders* 1% 47% Promoter & Promoter Group 53% Public ESOP Trust Syngene’s Share Information* NSE Ticker BSE Ticker Market Cap (Rs. Mn) % free-float^ Free-float market cap (Rs. Mn) Share Outstanding (Mn) SYNGENE 539268 2,57,438 47% 1,21,810 403 • As on 30th June 2025 • ^ Free float includes shares held by public and in ESOP Trust Putting Science to Work 29 For more details Visit our website www.syngeneintl.com https://www.linkedin.com/company/syngene-international-limited https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ
IR Contact
Nandini Agarwal / Shubham Jain +91 7838382527 / +91 6377651994 investor@syngeneintl.com nandini.agarwal@syngeneintl.com shubham.jain@syngeneintl.com
← All transcriptsSYNGENE stock page →